This study is currently not recruiting participants.

Type 1 Diabetes TrialNet Protocol TN-18 CTLA4-Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus

Study on Investigational Medication for Delaying Type 1 Diabetes

Not Recruiting
6 years - 45 years
All
Phase N/A
1 Location

Brief description of study.

The goal of this study is to learn if abatacept helps delay or prevent the development of type 1 diabetes in people who have relatives with this disease.

Detailed description of study

The goal of this study is to learn if abatacept helps delay or prevent the development of type 1 diabetes in people who have relatives with this disease.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetes - Type I
  • Age: 6 years - 45 years
  • Gender: All

This study investigates whether an investigational medication can delay or prevent type 1 diabetes in individuals who have relatives with this disease. Type 1 diabetes is a condition where the body's immune system attacks insulin-producing cells, leading to high blood sugar levels.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the effects on the development of type 1 diabetes.

  • Who can participate: Individuals aged X to Y who have relatives with type 1 diabetes may be eligible to participate in this study.
  • Study details: Participants will be randomly assigned to receive the investigational medication.
Updated on 19 Feb 2024. Study ID: 1301010310

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team